New York, NY, September 5th, 2023 – A2A Pharmaceuticals, a company dedicated to discovering and developing novel small molecules for genetically defined cancers, has announced the addition of Dr. Ozgur Sahin and Dr. Erden Banoglu to its Scientific Advisory Board (SAB). This strategic move aims to advance the TACC3 PPI small molecule inhibitor into clinical stages, with significant contributions from these distinguished scientists in the field of cancer research and drug discovery.
Dr. Sotirios G. Stergiopoulos, President and CEO of A2A Pharmaceuticals, emphasized the importance of this addition for the development of their leading programs. Dr. Ozgur Sahin, with a background in cancer systems biology, and Dr. Erden Banoglu, specializing in medicinal and natural products chemistry, bring extensive expertise and recognition to the team. Their research and leadership roles in various institutions and industries highlight their contributions to cancer biology and new drug discovery.
This addition underscores A2A Pharmaceuticals’ commitment to enhancing its innovative treatments and bringing novel therapies to clinical practice.
